论文部分内容阅读
在我国国民经济的组成中,医药行业始终占有很重要的份额,特别是改革开放以来,我国已经形成了比较完备的医药工业体系和医药流通网络,逐步迈入世界制药大国的行列。而随着我国加入WTO后,随着政府相关部门对我国中小型制药企业的监管力度日益加强,以及《药品生产质量管理规范(GMP)》的强制执行,使得行业进入门槛增高,药企固定资产投资加大,医药行业现有的人才结构及素质已不能满足行业的需求,人才问题日益凸显,对医药行业而言,人才素质和人
In the composition of China’s national economy, the pharmaceutical industry has always occupied a very important share, especially since the reform and opening up, China has formed a relatively complete pharmaceutical industry system and pharmaceutical distribution network, and gradually entered the ranks of the world’s pharmaceutical giants. With China’s accession to the WTO, with the government’s relevant departments to strengthen the supervision of small and medium-sized pharmaceutical companies in China, as well as the implementation of the “GMP (Good Manufacturing Practices) (GMP)”, the industry entry barrier to increase, pharmaceutical companies fixed assets With the increase of investment, the existing talent structure and quality of the pharmaceutical industry can no longer meet the needs of the industry. Talent issues have become increasingly prominent. For the pharmaceutical industry, talent quality and people